Edwards Lifesciences Corp EW
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $6.1B | +12% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Gross profit | $4.7B | +10% | FY ending Dec 31, 2025 |
| Operating income | $1.3B | -8% | FY ending Dec 31, 2025 |
| Net income | $1.1B | -74% | FY ending Dec 31, 2025 |
| Earnings per share | $1.83 | -74% | FY ending Dec 31, 2025 |
| Research & development | $1.1B | +2% | FY ending Dec 31, 2025 |
| Cash from operations | $1.6B | +194% | FY ending Dec 31, 2025 |
| Capital spending | $260.2M | +3% | FY ending Dec 31, 2025 |
| Share buybacks | $893.4M | -23% | FY ending Dec 31, 2025 |
| Cash | $2.9B | -4% | FY ending Dec 31, 2025 |
| Long-term debt | $598.3M | +0% | FY ending Dec 31, 2025 |
| Shareholders' equity | $10.3B | +3% | FY ending Dec 31, 2025 |
| Shares outstanding | 581M | -1% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 0 open-market buys ($0) and 43 sales ($27.7M) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Daniel J. LippisCVP, TAVR | Soldpre-set plan | 619 | $85.65 | $53K | Oct 8, 2026 |
| Daniel J. LippisCVP, TAVR | Soldpre-set plan | 619 | $87.51 | $54K | Sep 11, 2026 |
| Andrew M. DahlSVP, Corporate Controller | Sold | 544 | $91.06 | $50K | Aug 31, 2026 |
| Annette BrulsCVP, EMEACLA | Sold | 2,644 | $89.98 | $238K | Aug 28, 2026 |
| Daveen ChopraCVP, TMTT, Surgical & IHFM | Sold2 fills | 31,800 | $91.02 avg | $2.9M | Aug 26, 2026 |
| Wayne MarkowitzCVP, JAPAC | Sold | 1,240 | $91.47 | $113K | Aug 26, 2026 |
| Daniel J. LippisCVP, TAVR | Soldpre-set plan | 619 | $92.03 | $57K | Aug 11, 2026 |
| Wayne MarkowitzCVP, JAPAC | Sold | 146 | $86.03 | $13K | Jul 30, 2026 |
| Wayne MarkowitzCVP, JAPAC | Sold | 9,628 | $85.06 | $819K | Jul 28, 2026 |
| Bernard J ZovighianCEO, Director | Sold | 2,921 | $83.93 | $245K | Jul 27, 2026 |
| Daniel J. LippisCVP, TAVR | Soldpre-set plan | 619 | $91.70 | $57K | Jul 10, 2026 |
| Daniel J. LippisCVP, TAVR | Soldpre-set plan | 619 | $91.40 | $57K | Jun 30, 2026 |
| Bernard J ZovighianCEO, Director | Soldpre-set plan | 523 | $87.92 | $46K | Jun 17, 2026 |
| Andrew M. DahlSVP, Corporate Controller | Sold | 568 | $86.08 | $49K | May 29, 2026 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Sold | 23,145 | $86.42 | $2.0M | May 27, 2026 |
| Daveen ChopraCVP, TMTT & Surgical | Sold | 1,500 | $84.60 | $127K | May 22, 2026 |
| Daniel J. LippisCVP, TAVR | Soldpre-set plan | 620 | $81.14 | $50K | May 18, 2026 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Sold2 fills | 17,968 | $81.96 avg | $1.5M | May 15, 2026 |
| Bernard J ZovighianCEO, Director | Soldpre-set plan2 fills | 36,351 | $77.93 avg | $2.8M | May 12, 2026 |
| Wayne MarkowitzCVP, JAPAC | Sold | 593 | $79.73 | $47K | May 11, 2026 |
| Daniel J. LippisCVP, TAVR | Soldpre-set plan | 1,019 | $83.98 | $86K | May 4, 2026 |
| Daniel J. LippisCVP, TAVR | Soldpre-set plan2 fills | 1,019 | $83.01 avg | $85K | May 1, 2026 |
| Scott B. UllemCVP, Chief Financial Officer | Soldpre-set plan2 fills | 13,000 | $80.04 avg | $1.0M | Apr 9, 2026 |
| Daniel J. LippisCVP, TAVR | Soldpre-set plan | 1,019 | $80.98 | $83K | Apr 6, 2026 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Soldpre-set plan2 fills | 22,680 | $80.16 avg | $1.8M | Apr 2, 2026 |
| Scott B. UllemCVP, Chief Financial Officer | Soldpre-set plan2 fills | 13,000 | $84.92 avg | $1.1M | Mar 11, 2026 |
| Daniel J. LippisCVP, TAVR | Soldpre-set plan | 1,019 | $85.38 | $87K | Mar 11, 2026 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Soldpre-set plan | 11,340 | $85.93 | $974K | Mar 2, 2026 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Sold | 24,000 | $83.84 | $2.0M | Feb 25, 2026 |
| Bernard J ZovighianCEO, Director | Sold2 fills | 22,430 | $76.67 avg | $1.7M | Feb 12, 2026 |
| Daniel J. LippisCVP, TAVR | Soldpre-set plan | 1,019 | $85.70 | $87K | Jan 9, 2026 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Soldpre-set plan2 fills | 11,340 | $85.66 avg | $971K | Jan 6, 2026 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Sold2 fills | 11,386 | $83.76 avg | $954K | Dec 12, 2025 |
| Heisz Leslie StoneDirector | Sold | 2,615 | $83.41 | $218K | Dec 12, 2025 |
| Daniel J. LippisCVP, JAPAC | Soldpre-set plan | 1,019 | $84.03 | $86K | Dec 12, 2025 |
| Daveen ChopraCVP, TMTT & Surgical | Sold | 2,000 | $84.38 | $169K | Dec 11, 2025 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Soldpre-set plan | 11,340 | $83.83 | $951K | Dec 10, 2025 |
| Bernard J ZovighianCEO, Director | Soldpre-set plan | 3,863 | $83.45 | $322K | Dec 10, 2025 |
| Scott B. UllemCVP, Chief Financial Officer | Soldpre-set plan | 7,700 | $84.47 | $650K | Dec 9, 2025 |
| Bernard J ZovighianCEO, Director | Soldpre-set plan | 21,487 | $85.21 | $1.8M | Dec 8, 2025 |
Other insider moves (99): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Daniel J. LippisCVP, TAVR | Option exercisepre-set plan | 619 | $72.68 | $45K | Oct 8, 2026 |
| Wayne MarkowitzCVP, JAPAC | Tax withholding | 568 | $84.37 | $48K | Sep 14, 2026 |
| Andrew M. DahlSVP, Corporate Controller | Tax withholding | 253 | $84.37 | $21K | Sep 13, 2026 |
| Daniel J. LippisCVP, TAVR | Option exercisepre-set plan | 619 | $72.68 | $45K | Sep 11, 2026 |
| Daveen ChopraCVP, TMTT, Surgical & IHFM | Tax withholding | 398 | $86.77 | $35K | Sep 11, 2026 |
| Wayne MarkowitzCVP, JAPAC | Tax withholding | 355 | $86.77 | $31K | Sep 11, 2026 |
| Daveen ChopraCVP, TMTT, Surgical & IHFM | Option exercise | 31,800 | $72.68 | $2.3M | Aug 26, 2026 |
| Daniel J. LippisCVP, TAVR | Option exercisepre-set plan | 619 | $72.68 | $45K | Aug 11, 2026 |
| Wayne MarkowitzCVP, JAPAC | Option exercise | 9,628 | $74.02 | $713K | Jul 28, 2026 |
| Bernard J ZovighianCEO, Director | Gift | 320 | – | – | Jul 27, 2026 |
| Bernard J ZovighianCEO, Director | Gift | 320 | – | – | Jul 27, 2026 |
| Annette BrulsCVP, EMEACLA | Tax withholding | 109 | $92.21 | $10K | Jul 11, 2026 |
| Daniel J. LippisCVP, TAVR | Option exercisepre-set plan | 619 | $72.68 | $45K | Jul 10, 2026 |
| Theodora MistrasCVP, Chief Financial Officer | Award2 fills | 99,920 | – | – | Jul 9, 2026 |
| Daniel J. LippisCVP, TAVR | Tax withholding | 377 | $95.18 | $36K | Jul 7, 2026 |
| Daniel J. LippisCVP, TAVR | Option exercisepre-set plan | 619 | $72.68 | $45K | Jun 30, 2026 |
| Daniel J. LippisCVP, TAVR | Option exercisepre-set plan | 620 | $72.68 | $45K | May 18, 2026 |
| Bernard J ZovighianCEO, Director | Giftpre-set plan | 26,640 | – | – | May 12, 2026 |
| Bernard J ZovighianCEO, Director | Giftpre-set plan | 26,640 | – | – | May 12, 2026 |
| Bernard J ZovighianCEO, Director | Tax withholdingpre-set plan | 26,198 | $79.96 | $2.1M | May 11, 2026 |
| Scott B. UllemCVP, Chief Financial Officer | Tax withholding | 11,004 | $79.96 | $880K | May 11, 2026 |
| Daveen ChopraCVP, TMTT & Surgical | Tax withholding | 7,538 | $79.96 | $603K | May 11, 2026 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Tax withholding | 7,469 | $79.96 | $597K | May 11, 2026 |
| Daniel J. LippisCVP, TAVR | Tax withholding | 362 | $79.96 | $29K | May 11, 2026 |
| Bernard J ZovighianCEO, Director | Option exercisepre-set plan | 47,207 | – | – | May 11, 2026 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Option exercise | 13,457 | – | – | May 11, 2026 |
| Daveen ChopraCVP, TMTT & Surgical | Option exercise | 13,583 | – | – | May 11, 2026 |
| Scott B. UllemCVP, Chief Financial Officer | Option exercise | 19,830 | – | – | May 11, 2026 |
| Bernard J ZovighianCEO, Director | Gift | 5,489 | – | – | May 11, 2026 |
| Bernard J ZovighianCEO, Director | Gift | 5,489 | – | – | May 11, 2026 |
| Bernard J ZovighianCEO, Director | Tax withholding | 5,398 | $82.76 | $447K | May 8, 2026 |
| Scott B. UllemCVP, Chief Financial Officer | Tax withholding | 1,661 | $82.76 | $137K | May 8, 2026 |
| Daveen ChopraCVP, TMTT & Surgical | Tax withholding | 1,141 | $82.76 | $94K | May 8, 2026 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Tax withholding | 1,038 | $82.76 | $86K | May 8, 2026 |
| Daniel J. LippisCVP, TAVR | Tax withholding | 450 | $82.76 | $37K | May 8, 2026 |
| Andrew M. DahlSVP, Corporate Controller | Tax withholding | 289 | $82.76 | $24K | May 8, 2026 |
| Wayne MarkowitzCVP, JAPAC | Tax withholding | 226 | $82.76 | $19K | May 8, 2026 |
| Annette BrulsCVP, EMEACLA | Tax withholding | 84 | $82.76 | $6,952 | May 8, 2026 |
| Bernard J ZovighianCEO, Director | Gift | 4,222 | – | – | May 8, 2026 |
| Bernard J ZovighianCEO, Director | Gift | 4,222 | – | – | May 8, 2026 |
| Nicholas J ValerianiDirector | Award | 5,127 | – | – | May 8, 2026 |
| Ramona SequeiraDirector | Award | 3,251 | – | – | May 8, 2026 |
| Steven R LorangerDirector | Award2 fills | 4,315 | – | – | May 8, 2026 |
| Paul A LavioletteDirector | Award | 3,251 | – | – | May 8, 2026 |
| Heisz Leslie StoneDirector | Award | 3,251 | – | – | May 8, 2026 |
| Kieran GallahueDirector | Award2 fills | 4,315 | – | – | May 8, 2026 |
| David T FeinbergDirector | Award | 3,251 | – | – | May 8, 2026 |
| Leslie C. DavisDirector | Award | 3,251 | – | – | May 8, 2026 |
| Bernard J ZovighianCEO, Director | Tax withholding | 4,153 | $83.20 | $346K | May 7, 2026 |
| Scott B. UllemCVP, Chief Financial Officer | Tax withholding | 1,373 | $83.20 | $114K | May 7, 2026 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Tax withholding | 831 | $83.20 | $69K | May 7, 2026 |
| Daveen ChopraCVP, TMTT & Surgical | Tax withholding | 674 | $83.20 | $56K | May 7, 2026 |
| Daniel J. LippisCVP, TAVR | Tax withholding | 309 | $83.20 | $26K | May 7, 2026 |
| Wayne MarkowitzCVP, JAPAC | Tax withholding | 264 | $83.20 | $22K | May 7, 2026 |
| Wayne MarkowitzCVP, JAPAC | Award | 5,200 | – | – | May 7, 2026 |
| Bernard J ZovighianCEO, Director | Award | 43,800 | – | – | May 7, 2026 |
| Donald E Jr BoboCVP,Strategy/Corp Development | Award | 7,850 | – | – | May 7, 2026 |
| Daniel J. LippisCVP, TAVR | Award | 7,850 | – | – | May 7, 2026 |
| Andrew M. DahlSVP, Corporate Controller | Award2 fills | 7,005 | – | – | May 7, 2026 |
| Daveen ChopraCVP, TMTT & Surgical | Award | 9,675 | – | – | May 7, 2026 |
Trades by members of Congress
4 members reported 3 buys and 3 sales since Mar 3, 2025. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Josh Gottheimer D | Sold | $1,001–$15K | Nov 19, 2025 | Dec 29, 2025 | Joint |
| Jefferson Shreve R | Sold | $50K–$100K | May 12, 2025 | Jun 22, 2025 | Self |
| Bruce Westerman R | Sold | $1,001–$15K | Apr 21, 2025 | May 12, 2025 | Self |
| Robert P. Bresnahan, Jr. R | Bought | $1,001–$15K | Apr 8, 2025 | May 8, 2025 | Self |
| Jefferson Shreve R | Bought | $15K–$50K | Apr 7, 2025 | May 8, 2025 | Self |
| Bruce Westerman R | Bought | $1,001–$15K | Mar 3, 2025 | Apr 16, 2025 | Self |
Latest SEC filings
- Insider plans to sell 144 · Aug 31, 2026
- Insider plans to sell 144 · Aug 28, 2026
- News filing: Executive or board change 8-K · Aug 28, 2026
- Insider plans to sell 144 · Aug 26, 2026
- Insider plans to sell 144 · Aug 26, 2026
- Insider plans to sell 144 · Aug 11, 2026
- Quarterly report 10-Q · Aug 4, 2026
- Insider plans to sell 144 · Jul 30, 2026
- Insider plans to sell 144 · Jul 30, 2026
- Insider plans to sell 144 · Jul 28, 2026
- Insider plans to sell 144 · Jul 27, 2026
- News filing: Quarterly results 8-K · Jul 23, 2026
- Insider plans to sell 144 · May 29, 2026
- Insider plans to sell 144 · May 29, 2026
- Insider plans to sell 144 · May 27, 2026
- Insider plans to sell 144 · May 22, 2026
- Insider plans to sell 144 · May 18, 2026
- Insider plans to sell 144 · May 15, 2026
- Insider plans to sell 144 · May 12, 2026
- Insider plans to sell 144 · May 11, 2026
- News filing: Executive or board change, Shareholder vote results 8-K · May 8, 2026
- Quarterly report 10-Q · May 6, 2026
- News filing: Executive or board change, Public announcement (Reg FD) 8-K · May 4, 2026
- Insider plans to sell 144 · May 4, 2026
- News filing: Quarterly results 8-K · Apr 23, 2026
About Edwards Lifesciences Corp
Business description
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Sector
- Industrial Applications and Services
- Headquarters
- Irvine, CA
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Exchange
- NYSE
- Filer size
- Large accelerated filer
- Formerly
- CVG CONTROLLED INC
- SEC company number (CIK)
- 1099800
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.